LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the appointment of Harold Rabinovitz, M.D., to its Scientific Advisory Board. Dr. Rabinovitz, M.D., is a Board Certified Dermatologist and a voluntary Clinical Professor of Dermatology at University of Miami School of Medicine. He is world-renown for his work in dermoscopy and confocal microscopy.
Dr. Rabinovitz graduated Cum Laude from Princeton University and received his medical degree from University of Miami School of Medicine. He performed his internship at Mt. Sinai Medical Center and completed his dermatology residency at New York University Medical Center.
Dr. Rabinovitz's research interests focus on identification of tumor characteristics with new research instruments and education on early tumor detection.
"Melanoma is the great masquerader and millions of moles have at least one feature that falls into the criteria dermatologists refer to as the ABCDEs of melanoma," said Dr. Rabinovitz. "That's why in addition to visually inspecting the skin, high-tech diagnostic tools can be helpful in determining whether a suspicious mole is actually a melanoma or a benign lesion."
DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit: dermtech.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171107005013/en/
Sarah Dion, MBA
VP, Sales and Marketing
Source: DermTech, Inc.